BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210304T140000
DTEND;TZID=Europe/Brussels:20210304T153000
DTSTAMP:20210225T120052Z
CREATED:20210211T123919Z
LAST-MODIFIED:20210225T120052Z
UID:1355-1614866400-1614871800@www.europabio.org
SUMMARY:Measuring the Economic Footprint of the Biotechnology Industry in Europe
DESCRIPTION:Landscape and Positions for Economic Development: Industry and policy discussions to deliver biotechnology in Europe. \n\n\n\n\n\nEuropean GDP benefitted by €38.5 bn in 2018\, in the recent study from EuropaBio ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’.  The study looked at the economic impact of the biotechnology industry within the (then) 28 European member states\, in terms of gross value added (GVA)\, employment and trade.  Including spill over effects\, that number rises to €78.7bn.  The direct contribution adds up to about 1.5% of total industrial GVA within the countries assessed\, supported by 223\,000 direct jobs rising to over 700\,000 with associated employment. \n\n\n\nVery few other sectors enhance quality of life\, knowledge\, innovation\, productivity\, andenvironmental protection as biotechnology does.  \n\n\n\nJoin EuropaBio on March 4 to find out more about the the economic footprint of biotechnology in Europe and be part of the discussion on its role in future economic recovery and delivering healthy people and planet.
URL:https://www.europabio.org/event/measuring-the-economic-footprint-of-the-biotechnology-industry-in-europe-landscape-and-positions-for-development/
CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/02/WebEx-Event-Banner-WifOR.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210303T084500
DTEND;TZID=Europe/Brussels:20210303T121500
DTSTAMP:20210212T163056Z
CREATED:20210203T212715Z
LAST-MODIFIED:20210212T163056Z
UID:1157-1614761100-1614773700@www.europabio.org
SUMMARY:Annual Conference on EU Law in the Pharmaceutical Sector
DESCRIPTION:Annual Conference on EU Law in the Pharmaceutical Sector (3-5 March 2021) \n\n\n\nObjective \n\n\n\nThis online conference will bring legal practitioners working with the pharmaceutical sector up-to-date on the latest relevant regulatory developments\, legislative initiatives and case law. \n\n\n\nKey topics \n\n\n\nImpact of recent rulings from the CJEU on supplementary protection certificates\, patent settlements\, and online sales of medicinal products Ongoing European Commission cases on competition lawTowards a European Health Data SpaceThe European Commission’s Pharmaceutical StrategyInitiatives related to Covid-19: shortage of medicines\, dependency on raw materials from outside the EU\, cooperation between Member StatesFair competition between pharmaceutical companies in times of Covid-19 and Brexit\n\n\n\nWho should attend? \n\n\n\nIn-house counsel\, lawyers in private practice\, lawyers in national ministries and authorities dealing with regulation of the sector. \n\n\n\nInteractive online event \n\n\n\nThe conference will be hosted on ERA’s own online platform. You will be able to interact immediately and directly with our top-level speakers and other participants. We will make the most of the technical tools available to deliver an intensive\, interactive experience. As the platform is hosted on our own server\, the highest security settings will be applied to ensure that you can participate safely in this high-quality online conference. \n\n\n\n\n\n\n\nNetworking \n\n\n\nNetworking opportunities where participants can meet each other and chat with speakers will be offered. \n\n\n\nEuropaBio Members can benefit of a 25% discount on the price. Please liaise with Martina Cilia (m.cilia@europabio.org) to receive detailed information on the discount code.
URL:https://www.europabio.org/event/annual-conference-on-eu-law-in-the-pharmaceutical-sector/
LOCATION:VIRTUAL\, Metzer Allee 4\, Trier\, D-54295\, Germany
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-ERA.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210302T090000
DTEND;TZID=Europe/Brussels:20210305T170000
DTSTAMP:20210212T163115Z
CREATED:20210209T163156Z
LAST-MODIFIED:20210212T163115Z
UID:1278-1614675600-1614963600@www.europabio.org
SUMMARY:Oncology Virtual Partnering (Member Discount)
DESCRIPTION:Oncology is one of the most challenging areas for research and development\, but there are critical junctures where the right environment is crucial for success – and where partnering can help bring the best science forward. \n\n\n\nAt Inova\, our aim is to facilitate the bridge between science and business. Inova and Biotechnology Innovation Organization (BIO)\, in partnership with Evaluate\, are organizing this Oncology Virtual Partnering Event. Through online one-to-one meetings taking place 2 – 5 March\, researchers\, biotechs and biopharmaceutical companies will discuss the latest research from oncology congresses\, pitch ideas and partner to prioritize the most promising research efforts. \n\n\n\nThis event will leverage Inova and Biotechnology Innovation Organization (BIO)’s biopharma industry expertise\, leading digital networking platform and years of experience organizing partnering events to connect scientific and business communities for the benefit of patients worldwide. \n\n\n\n\n\n\n\nEuropaBio Members can benefit from 15% discount. Please liaise with Martina Cilia for further details.
URL:https://www.europabio.org/event/oncology-virtual-partnering-member-discount/
LOCATION:VIRTUAL\, Inova Software\, 89 Rue Tronchet\, Lyon\, 69006\, France
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Oncology.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210301T093000
DTEND;TZID=Europe/Brussels:20210302T170000
DTSTAMP:20210212T163133Z
CREATED:20210203T211251Z
LAST-MODIFIED:20210212T163133Z
UID:1150-1614591000-1614704400@www.europabio.org
SUMMARY:1st International Conference on Rare Diseases
DESCRIPTION:1st International Conference on Rare Diseases \n\n\n\nDifferent infrastructures and organisational arrangements are required in each country to address the healthcare needs of its rare disease population in an effective way. Whether a single rare disease affects thousands or only a handful of individuals\, they all share similar challenges to get a timely diagnosis\, face the same barriers to access highly specialized care and treatment options and need to deal with a substantial psychosocial burden. \n\n\n\nThe health of people living with a rare disease should not be left to luck or chance especially amidst the COVID-19 pandemic. Planning ahead requires all stakeholders to acknowledge their individual responsibility to build a successful pathway from diagnosis to access and at the same time\, commit to work together in a much more agile and coordinated way than what we have seen so far. If we fail to do so\, we will have failed the 30 million people living with a rare disease in Europe. \n\n\n\nThe 1st International Conference on Rare Diseases “Building a Pathway from Diagnosis to Access” recognises that the next decade holds great potential for improvement and that while we cannot predict the future\, we all have a role in preparing for it. As the EU shapes its future regulations\, strategies and access policies\, this conference will serve as an opportunity to press the ‘pause button’ and take the time to co-create policy options today that can lead to a better patient journey in the future. \n\n\n\nEngaging all stakeholders to take action\, the 1st International Conference on Rare Diseases aspires to bring together all stakeholders in the rare disease community – patient representatives\, policy makers\, clinicians\, researchers\, industry representatives\, payers and regulators to exchange invaluable knowledge with the aim to enhance dialogue and promote policy changes to help build a better pathway from Diagnosis to Access for Rare Diseases.
URL:https://www.europabio.org/event/1st-international-conference-on-rare-diseases/
LOCATION:VIRTUAL\, 338. Kleisthenous Str.\, Gerakas\, Attiki\, 15344\, Greece
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Rare-Diseases.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210223T110000
DTEND;TZID=Europe/Brussels:20210223T123000
DTSTAMP:20210225T111812Z
CREATED:20210203T204218Z
LAST-MODIFIED:20210225T111812Z
UID:1135-1614078000-1614083400@www.europabio.org
SUMMARY:#EUIndustryWeek2021: The next Industrial Revolution is a Bio Revolution
DESCRIPTION:Global challenges like COVID-19 and climate change require a range of solutions\, including those coming from innovative biotechnology. Life sciences and biotechnology is a key industrial sector which can play a transformative role in securing the EU’s competitive edge in health and sustainability.From new treatments for rare diseases to bio-based products\, biotechnology can revolutionize our approach to global challenges\, paving the way for an industrial revolution driven by the life sciences. \n\n\n\nJoin EuropaBio for presentations and discussion around the key issues where biotechnology is making a difference and how the scientific and business landscape will enable it in the future.Our panel will discuss the innovation potential of industrial and healthcare biotechnology for long term and future EU competitiveness\, including biotech SMEs as a critical part of the EU life sciences ecosystem\, and the need for a strategic approach for investment and innovation.Confirmed speakers: \n\n\n\nDr Marcus Remmers\, CTO\, Royal DSMMr Geoffrey Pot\, VP operations\, Takeda & bio.be ChairmanProf Isabel Rocha\, Pro-Rector of Nova University of LisbonDr Armin Spök\, TU Graz\, CHIC H2020 Project\n\n\n\nThis webinar is hosted by EuropaBio under the umbrella of the EU Industry Days and will be moderated by Dr Claire Skentelbery (Director-General\, EuropaBio).You can download below the speakers’ presentations: \n\n\n\nEU-Industry-Days-EuropaBio-Event-Armin-Spoek-PresentationDownload\n\n\n\nEU-Industry-Days-EuropaBio-Event-Geoffrey-Pot-PresentationDownload\n\n\n\nEU-Industry-Days-EuropaBio-Event-Isabel-Rocha-PresentationDownload\n\n\n\nEU-Industry-Days-EuropaBio-Event-Marcus-Remmers-PresentationDownload
URL:https://www.europabio.org/event/euindustryweek2021-the-next-industrial-revolution-is-a-bio-revolution/
LOCATION:VIRTUAL\, Avenue des Arts 53\, Brussels\, 1000\, Belgium
CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-EU-Ind.-Week-Ebio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210218T113000
DTEND;TZID=Europe/Brussels:20210218T130000
DTSTAMP:20210212T163254Z
CREATED:20210127T062632Z
LAST-MODIFIED:20210212T163254Z
UID:720-1613647800-1613653200@www.europabio.org
SUMMARY:EuropaBio National Associations Council: Brexit Impact for UK and Europe (Member-only webinar)
DESCRIPTION:As part of the EuropaBio National Associations Council\, this meeting kick starts a long term Brexit monitoring Group within EuropaBio which will support members to understand and manage Brexit changes and for the National Associations Council to identify priority topics for joint communications.
URL:https://www.europabio.org/event/brexit-impact-monitoring-members-only/
CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/02/Event-Banner-Brexit-NAC.png
END:VEVENT
END:VCALENDAR